Navigation Links
SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update
Date:5/13/2008

e hereof.

SGX PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

(unaudited)

Three Months Ended

March 31,

2008 2007

Revenue:

Collaborations and

commercial agreements $15,001 $5,647

Grants 1,971 5,321

Total revenue 16,972 10,968

Operating expenses:

Research and development 11,349 10,018

General and administrative 2,121 2,233

Total operating expenses 13,470 12,251

Income (loss) from operations 3,502 (1,283)

Interest income and expense, net 219 185

Net income (loss) $3,721 $(1,098)

Net income (loss) per common share:

Basic $0.18 $(0.07)

Diluted $0.18 $(0.07)

Shares used to compute

basic and diluted net

income (loss) per common share:

Basic 20,530 15,228

Diluted 21,089 15,228

Three Months Ended Three Months Ended

March 31, 2008 (1) March 31, 2007 (1)

Stock- Stock-

based Reported based Reported

compensation GAAP compensation GAAP

non-GAAP expense results non-GAAP expense results

Net income (loss) $4,347 $(626) $3,721 $(109) $(989) $(1,098)

Basic net income

(loss) per common

share:
'/>"/>

SOURCE SGX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic ... it has received a $1.5M Phase II SBIR ... to further develop its therapeutic agent to reduce ... need in end stage renal disease (ESRD) patients ... National Institute of Diabetes and Digestive and Kidney ...
(Date:8/26/2015)... KONG , Aug. 26, 2015 China ... China,s leading provider of cord ... stem cell storage services, today announced that the Company ... Limited ("MO2"), an entity wholly owned by Mr. Yuen ... Company, has acquired the outstanding shares (the "Shares") of  ...
(Date:8/26/2015)... ... 2015 , ... PRC Clinical, a Clinical Trial Management Expert CRO, ... in southern California. The Clinical Trial Management Expert CRO seeks to introduce more California-based ... , Stem Cell Meeting on the Mesa on October ...
(Date:8/25/2015)... UK (PRWEB) , ... August 25, 2015 , ... ... determining whether breast tissue lesions are cancerous is described by University of Illinois ... international society for optics and photonics. , In “ Breast cancer diagnosis using ...
Breaking Biology Technology:Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 2New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 3New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 4
... SEATTLE, Nov. 10, 2010 Dendreon Corporation (Nasdaq: ... has completed the submission of the post-approval supplement ... the Morris Plains, New Jersey manufacturing facility. Dendreon ... to manufacture PROVENGE. The standard U.S. Food and ...
... announces that a new stem cell gene and enzyme replacement ... with Tay-Sachs disease on November 2, 2010. Tay-Sachs is a ... heritage and in very rare cases families of Eastern European ... appear normal at birth but about six months of age ...
... SAN DIEGO, Nov. 10, 2010 SG Biofuels , ... Jatropha, today announced it has established a strategic partnership with ... Limited (NYSE: BG ), to research and develop ... SG Biofuels President and Chief Executive Officer ...
Cached Biology Technology:Dendreon Submits Post-Approval Supplement to the PROVENGE Biologics License Application for New Jersey Manufacturing Facility 2Tay-Sachs Disease Stem Cell Gene Enzyme Treatment 2SG Biofuels and Bunge Form Strategic Alliance to Process Jatropha Seeds Into Sustainable Crude Oil 2
(Date:8/6/2015)... Aug. 6, 2015 Synaptics Inc. (NASDAQ: ... interface solutions, today announced collaboration with Microsoft on ... 10. Microsoft leveraged Synaptics, deep expertise in human ... Through stringent testing, Synaptics, advanced ... with Microsoft,s Precision TouchPad (PTP) specification empowering OEMs ...
(Date:8/5/2015)... 2015 Transparency Market Research has ... - Global Industry Analysis, Size, Share, Growth, Trends and ... recognition is forecast to reach US$ 2,671.8 Mn by ... surveillance systems by civil and government agencies. This is ... terrorist activities across the globe that would elevate the ...
(Date:8/4/2015)... DUBLIN , Aug. 04, 2015 /PRNewswire/ ... ( http://www.researchandmarkets.com/research/nvh7k2/digital_forensics ) has announced the addition ... Component (Hardware, Software, and Service), Sub-Segment (Computer ... Cloud Forensics), Tool Types, Service, Vertical and ... report to their offering. By ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... A protein known to be overly active in ... to change the structural composition of mammary tissue, potentially ... from the Lombardi Comprehensive Cancer Center at Georgetown University ... Endocrine Society in Washington, DC, the scientists report that ...
... anymore waiting in the dark at this campus bus shelter. ... of engineering researchers at McMaster University has been installed to ... researchers are also hoping that the prototype will help boost ... is located on the west side of University Avenue between ...
... in new grants to study the use and impacts of ... viewed as a worrisome source of water and air pollution ... most important and least publicized environmental issues we face: Escaped ... water, and soil and has huge potential to contribute to ...
Cached Biology News:Protein linked to change in tissue that surround and support breast tumors 2Flexible solar strips light up campus bus shelter 2UC Davis begins $2.8 million in studies of agricultural nitrogen's impacts 2UC Davis begins $2.8 million in studies of agricultural nitrogen's impacts 3
Rabbit polyclonal to ErbB 2 (phospho Y1248) ( Abpromise for all tested applications). entrezGeneID: 2064 SwissProtID: P04626...
...
... Plus Western Blot Strong Antibody Stripping Solution ... Western blots that have been developed with ... It is not recommended for stripping colorimetric ... is not possible to effectively remove substrates ...
... 100 ml supplied as a 5x ... antibodies from membrane-bound proteins without destroying ... chemiluminescent or radioisotopic signals from blots. ... blots. Supplied as a 5X solution ...
Biology Products: